As this happened, Kepler upgraded its Novo Nordisk ADR [NVO] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Stifel’s analysts, who decreased its forecast for the stock in early March from “a Buy” to “a Hold”. Morgan Stanley began covering NVO with “an Equal-weight” recommendation on February 12, 2025. Bernstein revised its rating on January 06, 2025. It rated NVO as “a Mkt perform” which previously was an “an Underperform”.
Price Performance Review of NVO
On Tuesday, Novo Nordisk ADR [NYSE:NVO] saw its stock fall -2.38% to $64.49. Over the last five days, the stock has gained 4.69%. Novo Nordisk ADR shares have fallen nearly -25.03% since the year began. Nevertheless, the stocks have fallen -48.20% over the past one year. While a 52-week high of $148.15 was reached on 02/25/25, a 52-week low of $59.32 was recorded on 04/10/25. SMA at 50 days reached $78.05, while 200 days put it at $106.34.
Levels Of Support And Resistance For NVO Stock
The 24-hour chart illustrates a support level at 63.58, which if violated will result in even more drops to 62.68. On the upside, there is a resistance level at 65.67. A further resistance level may holdings at 66.85. The Relative Strength Index (RSI) on the 14-day chart is 38.06, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.74, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 54.33%. Stochastics %K at 42.60% indicates the stock is a holding.
How much short interest is there in Novo Nordisk ADR?
A steep rise in short interest was recorded in Novo Nordisk ADR stocks on 2025-03-31, growing by 1.15 million shares to a total of 14.66 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 13.51 million shares. There was a rise of 7.83%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 30, 2024 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $156 price target.
